期刊
VACCINE
卷 26, 期 29-30, 页码 3626-3633出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.04.073
关键词
influenza virus; HA protein; DNA vaccine; inactivated flu vaccine; prime-boost
资金
- NIAID NIH HHS [U19 AI062623-059002, U01 AI056536, U01 AI 056536, U19 AI062623, U19 AI62623, U01 AI056536-02] Funding Source: Medline
- NIDDK NIH HHS [5P30DK32520, P30 DK032520] Funding Source: Medline
The trivalent inactivated vaccine (TIV) is used to prevent seasonal influenza virus infection in humans, however, the immunogenicity of this vaccine may be influenced by the priming effect of previous influenza vaccinations or exposure to antigenically related influenza viruses. The current study examines the immunogenicity of a clinically licensed TIV in rabbits naive to influenza antigens. Animals were immunized with either the licensed TIV, a bivalent (H1 and H3) HA DNA vaccine or the combination of both. Temporal and peak level serum anti-influenza virus IgG responses were determined by enzyme-linked immunosorbent assay (ELISA). Functional antibody responses were measured by hemagglutination inhibition and microneutralization against either A/NewCaledonia//20/99 (H1N1) or A/Panama/2007/99 (H3N2) influenza viruses. Our results demonstrate that the immunogenicity of the TIV is low in sero-negative animals. More significantly, the heterologous DNA prime-TIV boost regimen was more immunogenic than the homologous prime-boost using either TIV or DNA vaccines alone. This finding justifies further investigation of HA DNA vaccines as a priming immunogen for the next generation of vaccines against seasonal or pandemic influenza virus infections. (C) 2008 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据